

### Asian Journal of Medicine and Health

11(2): 1-7, 2018; Article no.AJMAH.40623

ISSN: 2456-8414

# Cortisol and Metabolic Syndrome Components in Obese and Overweight Young Adults of a Nigerian Private University

Adediji, Isaac Oluwole<sup>1\*</sup>, Taiwo Timilehin Darasimi<sup>1</sup>, Adepoju Paul Olusegun<sup>2</sup>, Adelakun Ayodele Ademola<sup>3</sup>, Akinleye Waheed Akindele<sup>1</sup> and Afolabi Joy Oluwaseyifunmi<sup>1</sup>

<sup>1</sup>Clinical Chemistry Unit, Department of Medical Laboratory Science, Babcock University, Ilishan Remo, Ogun State, Nigeria.

<sup>2</sup>Histopathology Unit, Department of Medical Laboratory Science, Babcock University, Ilishan Remo, Ogun State, Nigeria.

<sup>3</sup>Department of Chemical Pathology, Ladoke Akintola University of Technology Teaching Hospital, Ogbomoso, Oyo State, Nigeria.

# Authors' contributions

This work was carried out in collaboration between all authors. Author AIO designed the study, wrote the protocol, and wrote the first draft of the manuscript. Authors APO and AWA managed the literature searches. Authors TTD and AJO managed the analyses of the study. Author AAA performed the statistical analysis. All authors read and approved the final manuscript.

#### **Article Information**

DOI: 10.9734/AJMAH/2018/40623

Editor(s):

(1) Triveni Krishnan, Division of Virology, National Institute of Cholera and Enteric Diseases, Kolkata, India.

Reviewers:

(1) Dhastagir Sheriff, Benghazi University, Libya.

(2) Ngo Nonga Bernadette, University of Yaounde I, Cameroon.

(3) Mra Aye, Melaka Manipal Medical College, Malaysia.

Complete Peer review History: http://www.sciencedomain.org/review-history/24149

Original Research Article

Received 17<sup>th</sup> January 2018 Accepted 31<sup>st</sup> March 2018 Published 14<sup>th</sup> April 2018

# **ABSTRACT**

**Background:** Metabolic syndrome is a cluster of metabolic abnormalities which confers upon an individual a substantial increase in cardiovascular disease risk – approximately twice as high as those without the syndrome.

**Aim:** The study assessed the relationship between serum cortisol and the components of metabolic syndrome among overweight and obese students.

**Materials and Methods:** A total of ninety (n=90) subjects were recruited for this study which consisted of thirty (30) obese participants, thirty (30) overweight individuals and thirty (30) normal weight individuals who served as controls. About 7 ml of venous blood sample was collected from each participant within the age range of 17-25 years and serum was extracted. Anthropometric measurements were determined using standard methods. Fasting blood glucose, HDL-cholesterol, triglycerides and total cholesterol were determined using enzymatic methods while serum cortisol was determined using enzyme-linked immunosorbent assay (ELISA) technique. Data obtained were statistically analyzed using ANOVA, Post-hoc, Pearson's correlation and P<0.05 was considered significant. In this study, metabolic syndrome was defined according to the National Cholesterol Education Program (NCEP) criteria.

**Results:** There was a significant increase in the level of serum cortisol in overweight and obese subjects in comparison to the control participants. There was also positive significant correlation between cortisol and glucose, cortisol and triglyceride. In contrast, there was a negative correlation between cortisol and HDL cholesterol in both overweight (r=-0.917, P=0.02) and obese (r=-0.365, P=0.04) subjects.

**Conclusion:** This study revealed that increased serum cortisol level in obese and overweight subjects correlates with more than two components of the metabolic syndrome. Taken together, data from this study revealed a noteworthy relationship between cortisol and metabolic syndrome among Nigerian young adults which suggests that metabolic stress is an underlying factor for elevated cortisol.

Keywords: Metabolic syndrome; cortisol; obese; overweight; young adults.

# 1. INTRODUCTION

The trend of obesity among young adults worldwide especially university undergraduate students is gradually escalating [1,2]. Young adults between the ages of 18-25 undergo significant life style changes during this period which make them vulnerable to energy imbalance leading to excessive weight gain [3,4].

The World Health Organization (WHO) defined overweight and obesity as body mass index ≥25 kg/m² and ≥30 kg/m² respectively and they are associated with diabetes mellitus, cardiovascular disease and several types of cancer [5-7]. Obesity dysregulates glucose and lipid metabolic processes and thus it is believed to be the driving force for metabolic syndrome, a complex web of metabolic risk factors consisting of dysglycaemia, atherogenic dyslipidemia, hypertension, procoagulant state [8-10].

Contrary to the impression οf manv people in Africa that overweight and obesity are common among young adults in the western countries. due their lifestyles to heavy consumption of calorie-rich diet, some studies have reported increase in the rate of obesity among people aged 15 years and above in Sub-Saharan Africa [11,12]. The prevalence of obesity among old and young adults in Nigeria, is of epidemic proportion [13-15]. Cross-sectional studies by Onyenekwu et al.

[16] and Adejumo et al. [17] reported prevalence of metabolic syndrome among overweight and obese young adults at a private university in Nigeria. It then means that, as obesity is escalating among young adults, there is a parallel increase in the incidence of metabolic syndrome.

Systemic stress induced by obesity causes dysregulation in the production of adipokines which contributes to the development of metabolic syndrome [18]. Such dysfunction could enhance the conversion of inactive cortisone to active cortisol through the expression of 11-betahydroxysteroid dehydrogenase type-1 [19, 20].

Cortisol is a glucocorticoid hormone whose major function is adaptation to biological stress. Moderate levels of cortisol are important for physiological functions. many However, chronically elevated levels could result into obesity and insulin resistance [21]. It has been demonstrated in both human and animal models that dysregulation of hypothalamic-pituitary adrenal (HPA) axis which leads to the increased secretion of cortisol, promotes the accumulation of fat cells and weight gain [22]. Although there have been previous conflicting reports about the relationship between cortisol and obesity, there is paucity of data on the association between cortisol and metabolic syndrome. This study is therefore designed to assess the relationship between cortisol and components of metabolic syndrome in young adults at a private university in Nigeria.

# 2. MATERIALS AND METHODS

A total of 90 apparently healthy undergraduate students of Babcock University, Ilishan Remo, Ogun state aged 17-25 years participated in this cross sectional study. They comprised of thirty (30) obese students and thirty (30) overweight students as test subjects. The control subjects were thirty (30) normal weight students. A semistructured questionnaire was used to obtain demographic data and information about medical conditions, current medications, alcohol use and smoking habits. Body weight in kilogram (kg) was measured using a standard weighing scale and height (m) was measured using a stadiometer. Body mass index was calculated as the ratio of body weight (kg) to the square of height (m<sup>2</sup>). Waist circumference was measured midpoint between the inferior margin of the last rib and the crest of the ileum using a measuring tape. Blood pressure was measured using a mercury sphygmomanometer with appropriate cuff size. Korotkoff phases 1 and 5 were used.

Participants whose BMI was above 30 kg/m<sup>2</sup> were classified as obese, those with body mass index between 25.0-29.9 kg/m<sup>2</sup> were classified as overweight subjects while control subjects were normal weight individuals having a body mass index between 18.5-24.9 kg/m<sup>2</sup>.

This study excluded individuals who take alcohol, those who smoke, individuals with HIV, individuals with hepatitis, those on medications and individuals who have other known chronic medical conditions such as hypertension. Underweight individuals and those unwilling to give their consent were also excluded from this study.

# 2.1 Defining Criteria for Metabolic Syndrome

Metabolic syndrome was diagnosed using National Cholesterol Education Program-Adult treatment Panel III (NCEP-ATPIII) criteria [23]. The defining criteria was the presence of any three or more of these features: waist circumference (male: ≥102 cm, female: ≥88 cm), elevated blood pressure (≥130/≥85 mmHg), elevated triglycerides: ≥150 mg/dL, reduced HDL-C (males: <40 mg/dL, females: <50 mg/dL) and elevated fasting plasma glucose (≥100 mg/dL).

# 2.2 Sample Collection and Assay Methodology

The blood sample was collected in the morning from the study participants, after overnight fast which lasted for 10-12 hours. About 7 ml of venous blood was obtained from the cubital vein of each study participant, using pyrogen-free disposable vacutainer tubes. About 3 ml of venous blood was collected into fluoride oxalate bottle for the assay of fasting plasma glucose (FPG) which was performed within 12 hours, while 4ml was collected into plain bottle and was centrifuged at 4000 rpm for 3 minutes to obtain serum which was aliquoted into small vial and stored at -20°C for the determination of HDL-C, triglycerides (TG) and cortisol.

Plasma glucose was determined by the glucose oxidase method (Randox Laboratories Ltd., UK). Triglyceride (TG) was determined using standard enzymatic method (Randox Laboratories Ltd., UK) and high density lipoprotein-cholesterol (HDL-c) was determined by a two-step procedure using a precipitant to isolate non-HDL-c component in the plasma and this was followed by quantitative determination of HDL-c by standard enzymatic method for cholesterol determination (Randox Laboratories Ltd., UK). Serum cortisol was determined using ELISA (GenWay Biotech Inc., USA).

#### 2.3 Statistical Analysis

Data analysis was done using the statistical package for social sciences (SPSS  $17^{th}$  edition) computer software. Comparison of variables between groups was done using one-way analysis of variance (ANOVA) followed by a *post-hoc* test, while Pearson's correlation was used to determine the relationship between variables. All tests were two-tailed, and P < 0.05 was considered to be statistically significant.

# 3. RESULTS

Table 1 shows the frequency of metabolic syndrome components among obese and overweight subjects. Among the obese subjects, the proportion of those who had elevated blood pressure was 50% (15 participants), reduced HDL-C was 43.3% (13 participants), elevated TG was 16.7% (5 participants) and elevated FBG was 30% (9 participants). Among overweight subjects, the proportion of those who had

elevated blood pressure was 33.3% (10 participants), reduced HDL-C was 33.3% (10 participants), elevated TG was 6.7% (2 participants) and elevated FBG was 20% (6 participants).

Table 2 shows the proportion of obese and overweight subjects who had metabolic syndrome. Among obese and overweight subjects, 33.3% and 20% respectively had metabolic syndrome.

The anthropometric and biochemical parameters of the study participants are presented in Table 3. The test and control groups were compared using ANOVA and post hoc. There were remarkable significant increases in the mean waist circumference, systolic BP, diastolic BP, triglyceride, glucose, HDL cholesterol and cortisol (*P*< 0.001) in the test group when compared with the control group.

Table 4 shows correlation between cortisol and metabolic syndrome components in overweight subjects. There was significant positive correlation between cortisol and triglyceride (r= 0.014, *P*<0.05) meanwhile, there was a negative correlation between cortisol and HDL cholesterol (r= -0.917, *P*<0.05). There was no significant correlation between cortisol and waist circumference, diastolic blood pressure and systolic blood pressure.

Table 5 shows correlation between cortisol and metabolic syndrome components in obese subjects. There was significant positive correlation between cortisol and glucose (r=0.383, *P*<0.05), cortisol and triglyceride (r=0.393, *P*<0.05) meanwhile, there was a negative correlation between cortisol and HDL cholesterol (r=-0.365, *P*<0.05). Furthermore, there was no significant correlation between cortisol and waist circumference, diastolic blood pressure and systolic blood pressure.

Table 1. Frequency of components of metabolic syndrome in obese and overweight subjects

Metabolic syndrome components	Obese (n=30)	Overweight (n=30)
High blood pressure	15 (50%)	10 (33.3%)
Elevated FBG	9 (30%)	6 (20%)
Elevated TG	5 (16.7%)	2 (6.7%)
Reduced HDL	13 (43.3%)	10 (33.3%)

Table 2. Proportion of study participants with metabolic syndrome using NCEP-ATP III criteria

Subjects	Metabolic syndrome	No metabolic syndrome
Obese (n=30)	10 (33.3%)	20 (66.7%)
Overweight (n=30)	6 (20%)	24 (80%)
Control (n=30)	0 (0%)	30 (100%)

Table 3. Characteristics of study participants

Parameters	Obese subjects n=30	Overweight subjects n=30	Control subjects n=30	F	P-value
WC (cm)	108.42±9.41 <sup>a, b</sup>	92.18±10.30 <sup>a, c</sup>	78.36±7.60 <sup>b, c</sup>	80.950	0.000*
SBP (mmHg)	131.03±16.30 <sup>a</sup>	128.27±11.37 <sup>a</sup>	114.47±12.60 <sup>b, c</sup>	12.970	0.000*
DBP (mmHg)	85.07±13.24 <sup>a</sup>	81.47±9.48 <sup>a</sup>	73.40±6.60 <sup>b, c</sup>	10.400	0.000*
FBG (mg/dl)	110.57±24.47 <sup>a, b</sup>	98.83±22.842 <sup>a</sup>	86.63±11.640 <sup>b</sup>	4.163	0.001*
HDL-C (mg/dl)	46.3±13.39 <sup>a</sup>	40.077±13.3 <sup>a</sup>	53.183±13.76 <sup>b, c</sup>	7.083	0.001*
TG (mg/dL)	114.582±55.84 <sup>a</sup>	108.243±55.856 <sup>a</sup>	72.447±35.54 <sup>b, c</sup>	6.295	0.003*
Cortisol (ng/mL)	190.97±55.93 <sup>a, b</sup>	156.37±54.92 <sup>a, c</sup>	115.11±53.31 <sup>b, c</sup>	13.920	0.000*

Results are expressed in mean±standard deviation. \* Statistically significant at the levels indicated, a= significantly different from control subjects; b= significantly different from overweight subjects; c= significantly different from obese subjects. WC-waist circumference; SBP-systolic blood pressure; DBP-diastolic blood pressure; FBG-fasting blood glucose; HDL-C-high density lipoprotein-cholesterol; TG-triglyceride.

Table 4. Correlation between cortisol and metabolic syndrome components in overweight subjects

Cortisol	r	P-value
HDL-C	-0.917	0.02*
WC	0.16	0.40
SBP	0.824	0.05*
DBP	0.232	0.218
FBG	0.493	0.04*
TG	0.104	0.03*

\*Statistically significant at the levels indicated

Table 5. Correlation between cortisol and metabolic syndrome components in obese subjects

Cortisol	r	P-value	
HDL-C	-0.365	0.04*	
WC	0.02	0.907	
SBP	0.347	0.06	
DBP	0.245	0.191	
FBG	0.383	0.03*	
TG	0.393	0.006*	

\*Statistically significant at the levels indicated

#### 4. DISCUSSION

In this study, we assessed obese and overweight young adults in a Nigerian University using NCEP-ATP III criteria for metabolic syndrome. It was observed that one-fourth of the test subjects had metabolic syndrome although there was no correlation between cortisol and circumference, an observation which had also been reported by [24-26]. Glucocorticoids play active roles in human adipocyte differentiation and redistribution from peripheral to central depots [27,28]. The current study revealed increase in serum cortisol levels among overweight and obese volunteers. An explanation for the significantly higher levels of cortisol observed in this study was provided by [29, 30] and they implicated increased expression of 11βhydroxysteroid dehydrogenase type 1 (11- β HSD1) which catalyzes enhanced conversion of inactive cortisone to active cortisol in obesity. High cortisol levels exhibited by obese individuals, could also be in response to increased production of adipokines [18, 31].

The current study also revealed significant positive correlation between triglycerides and cortisol. This is in agreement with previous studies by [32-35]. This observation affirmed the interrelationship among the process of lipoprotein metabolism and therefore, any fundamental metabolic defect such as increased fasting

triglyceride, decreased HDL cholesterol, and increased small dense LDL particles could be for responsible dyslipidemic changes that are seen as part of the components of metabolic syndrome.

This study also established a strong correlation between cortisol and glucose. This is in agreement with the findings of [22, 36] and this that glucocorticoid observation suggests mediates hepatic gluconeogenesis, thereby leading to the elevation of fasting glucose levels in the test subjects. In addition to this mechanism, the inhibition of insulin action on skeletal muscles and the potentiation of insulin action on adipose tissues is exhibited by glucocorticoids. Furthermore Andrews et al. [37] and McMillen et al. [38] reported that cortisol potentiates the lipolytic action of the ß adrenergic receptors which are exclusively predominant in visceral adipose tissue, thus increasing free fatty acid flux and promoting insulin resistance which will ultimately give rise to metabolic syndrome.

#### 5. CONCLUSION

This study has been able to establish that elevated serum cortisol level in obese and overweight study subjects positively correlates with more than two components of metabolic syndrome. It has also revealed a striking relationship between cortisol and metabolic syndrome among the study participants which are Nigerian young adults.

While results from larger cross-sectional studies would be far-reaching and would play a significant role in understudying the observations reported in this study among participants from different population, race and ethnic groups, longitudinal studies would also facilitate even better understanding of the observed parameters and changes in the study participants over a given period of time.

#### CONSENT

All authors declare that 'written informed consent was obtained from the participants enlisted for this study'.

#### ETHICAL APPROVAL

Informed written consent was obtained from each participant who enrolled for this study and ethical clearance was granted by Babcock University Health Research Ethics Committee (BUHREC).

#### **COMPETING INTERESTS**

Authors have declared that no competing interests exist.

# **REFERENCES**

- Anderson DA, Shapiro JR, Lundgren JD. The freshman year of college as a critical period of weight gain: An initial evaluation. Eat Behaviours. 2003;4:367-369.
- Poobalan A, Aucott L. Obesity among young adults in developing countries. A systematic overview. Curr Obes Rep. 2016:5:2-3.
- Aucott L, Poobalan A, McCallum M, Smith WCS. Mental well being related to lifestyle and risky behaviours in 18–25 year old: evidence from North East Scotland. Int J Pub Health Res. 2014;4:431–440.
- 4. Poobalan AS, Aucott LS, Clarke A, Smith WCS. Diet behavior among young people in transition to adulthood (18–25 year olds): A mixed method study. Health PsycholBehav Med. 2014;2:909–928.
- World Health Organization. Fact sheet on Obesity; 2010.
   Available: <a href="http://www.who.int/topics/obesity/en/">http://www.who.int/topics/obesity/en/</a>
- 6. Cook S, Weitzman M, Auinger P. Prevalence of a metabolic syndrome phenotype in adolescents: Findings from the third National Health and Nutrition Examination Survey, 1988–1994. Arch Pediatr Adolesc Med. 2003;157(8):821–827.
- Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, Amann M, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: A systematic analysis for the Global Burden of disease study 2010. Lancet. 2013;380:2224–2260.
- 8. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome: A new worldwide definition: A consensus statement from the international diabetes federation. Diabet Med. 2006;23:469-480.
- Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome. Circulation. 2009;120:1640-1645.
- Misra A, Khurana L. Obesity and the metabolic syndrome in developing countries. J. Clin Endocrinol Metab. 2008;93:9–30.

- Ono T, Guthold R, Strong K. WHO global comparable estimates: 2005 Global Infobase data for saving lives; 2012. Available: <a href="https://apps.who.int/infobase/Index.aspx">https://apps.who.int/infobase/Index.aspx</a>
- Popkin BM, Adair LS, Ng SW. Global nutrition transition and the pandemic of obesity in developing countries. [Review]. Nutr Rev. 2012;70:3–21.
- Ejike CECC, Ijeh II. Obesity in young- adult Nigerians: Variations in prevalence determined by anthropometry and bioelectrical impedance analysis, and the development of % body fat prediction equations. International Archives of Medicine. 2012;5:22.
- Ijezie CI, Chukwu A, John C, Ohagwu KA, Imoh MA, Isa SE, Ogah SO, Oviasu E. Prevalence of overweight and obesity in adult Nigerians – a systematic review. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2013;6:43– 47. Dove Medical Press Ltd.
- 15. Akarolo-Anthony SN, Willett WC, Spiegelman D, Adebamowo CA. Obesity epidemic has emerged among Nigerians. BMC Public Health. 2014;14:455.
- Onyenekwu CP, Dada AO, Babatunde OT. The prevalence of metabolic syndrome and its components among overweight and obese Nigerian adolescents and young adults. Niger J Clin Pract. 2016;19:1-7.
- Adejumo EN, Adediji IO, Olusanya TO, Omodiale PE, Ojedele MT. Evaluation of insulin resistance and metabolic syndrome components in undergraduates of a Nigerian Private University. Journal of Life & Physical Sciences. actaSATECH. 2017; 9(1):128-139.
- 18. Esposito K, Ciotola M, Schisano B, Misso L, Giannetti G. Oxidative stress in the metabolic syndrome. J Endocrinol Invest. 2006;29:791-795.
- Stewart PM, Boulton A, Kumar S, Clark PM, Shackleton CH. Cortisol metabolism in human obesity: impaired cortisone-cortisol conversion in subjects with central adiposity. J Clin Endocrinol Metab. 1999; 84:1022-1027.
- Anagnostis P, Katsiki N, Adamidou F, Athyros VG, Karagiannis A, Kita M, Mikhailidis DP. 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders. Metabolism. 2013;62(1):21-23.

- Schacke H, Docke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther. 2002; 96(1):23-43.
- 22. Bjontorp P, Holm G, Rosmond R. Hypothalamic arousal, insulin-resistance and type 2 diabetes mellitus. Diabet Med. 1999;16:373-381.
- National Cholesterol Education Program (NCEP). Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285: 2486–2497.
- Ljung T, Andersson B, Bengtsson B, Björntorp P, Mårin P. Inhibition of cortisol secretion by dexamethasone in relation to body fat distribution: Adose-response study. Obes. Res. 1996;4:277–282.
   Available:http://dx.doi.org/10.1002/j.1550-8528.1996.tb00546.x
- 25. Ward AM, Fall CH, Stein CE, Kumaran K, Veena SR, Wood PJ, Syddall HE, Phillips DI. Cortisol and the metabolic syndrome in South Asians. Clin Endocrinol. 2003; 58:500–505.
- Champaneri S, Xu X, Carnethon MR, Bertoni AG, Seeman T, DeSantis AS, Diez Roux A, Shrager S, Golden SH. Diurnal salivary cortisol isassociated with body mass index and waist circumference: The multiethnic study of atherosclerosis. Obesity (Silver Spring). 2013;21:E56–E63, Available: <a href="http://dx.doi.org/10.1002/oby.200">http://dx.doi.org/10.1002/oby.200</a>
- 27. Mårin P, Darin N, Amemiya T, Andersson B, Jern S, Björntorp P. Cortisol secretion in relation to body fat distribution in obese premenopausal women. Metabolism. 1992;41(8):882-886.
- 28. Swenson L, Knodel DH. Adrenal function. Clinical chemistry. 5<sup>th</sup> ed. Philadelphia Lippincott Williams and Wilkins. 2005;415.
- Stewart PM, Toogood AA, Tomlinson JW. Growth hormone, insulin-like growth factor-

- I and the cortisol-cortisone shuttle. Horm Res. 2001;56(9):1-6.
- Terzolo M, Bovio S, Pia A, Osella G, Borretta G, Angeli A, Reimondo G. Subclinical Cushing's syndrome. Arq Bras Endocrinol Metabol. 2007;51:1272–1279.
- 31. Silha Josef V, Michal Krsek, Jan V Skrha, Petr Sucharda, Nyomba BLG, Liam J Murphy. Plasma resistin, adiponectin and leptin levels in lean and obese subjects: Correlations with insulin resistance. European Journal of Endocrinology. 2003; 149:331–335.
- 32. Duclos M, Marquez Pereira P, Barat P, Gatta B, Roger P. Increased cortisol bioavailability, abdominal obesity, and the metabolic syndrome in obese women. Obes Res. 2005;13:1157–1166.
- 33. Misra M, Bredella MA, Tsai P, Mendes N, Miller KK, Klibanski A. Lower growth hormone and hiaher cortisol associated with greater visceral adiposity, intramyocellular lipids. and insulin resistance in overweight girls. Am J Physiol Endocrinol Metab. 2008: 295:E385-E392.
- Sen Y, Aygun D, Yilmaz E, Ayar A. Children and adolescents with obesity and the metabolic syndrome have high circulating cortisol levels. Neuro Endocrinol Lett. 2008;29:141–145
- Weigensberg MJ, Toledo-Corral CM, Goran MI. Association between the metabolic syndrome and serum cortisol in overweight Latino youth. J Clin Endocrinol Metab. 2008;93:1372–1378.
- 36. Arner P. Regulation of lipolysis in fat cells. Diabetes Rev. 1996;4(1):450-463.
- Andrews RC, Herlihy O, Livingstone DEW, Andrew R, Walker BR. Abnormal cortisol metabolism and tissue sensitivity to cortisol in patients with glucose tolerance. J Clin Endocrinol Metab. 2002;87(12):5587-5593.
- McMillen IC, Robinson JS. Developmental origins of the metabolic syndrome: prediction, plasticity, and programming. Physiological Reviews. 2005;85(2):571-633.

© 2018 Adediji et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:
The peer review history for this paper can be accessed here:
http://www.sciencedomain.org/review-history/24149